Consistent with their findings, our data show that the inflammasomes in malignant cells are responsive to PAMPs, DAMPs and therapeutic treatment (Figs 3 and 4), and the interaction of tumour-derived IL-1β (over 64.2 pg/ml) and its receptors on the host cells can inhibit tumour growth and recurrence (Fig 5). This evidence concerns the gene IL1B and neoplasm.